Steve Brozak
Stock Analyst at WBB Securities
(0.05)
# 4,092
Out of 4,789 analysts
7
Total ratings
12.5%
Success rate
-24.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.14 | +996.49% | 1 | Apr 1, 2025 | |
| CDTX Cidara Therapeutics | Upgrades: Strong Buy | n/a | $18.92 | - | 1 | Sep 22, 2021 | |
| OMER Omeros | Maintains: Strong Buy | $75 → $100 | $7.91 | +1,164.22% | 2 | Jun 18, 2021 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $2.55 | +627,350.98% | 3 | May 28, 2021 |
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.14
Upside: +996.49%
Cidara Therapeutics
Sep 22, 2021
Upgrades: Strong Buy
Price Target: n/a
Current: $18.92
Upside: -
Omeros
Jun 18, 2021
Maintains: Strong Buy
Price Target: $75 → $100
Current: $7.91
Upside: +1,164.22%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $2.55
Upside: +627,350.98%